WS Investor
30 Apr 2026, 14:15
Eli Lilly Surges 8% as GLP-1 Drugs Deliver Another Blowout Quarter
Eli Lilly shares are up 8% in trading on April 30, on track for their biggest single-day gain in three months, after a Q1 2026 earnings report that smashed Wall Street expectations across the board.
Revenue rose 56% year-over-year to $19.8 billion, well above the $17.62 billion consensus, while adjusted EPS came in at $8.55, crushing expectations of $6.66. The engine behind the beat was familiar: Mounjaro revenues soared 125% to $8.66 billion, beating estimates by more than $1 billion, while Zepbound generated $4.16 billion in US revenue, up 80% year-over-year. Together, GLP-1 drugs accounted for roughly two-thirds of total sales. (CNBC, Invezz)
On guidance, Lilly raised full-year 2026 revenue guidance to $82 to $85 billion, up $2 billion from prior estimates, and lifted adjusted EPS guidance to $35.50 to $37 per share. (CNBC)
The new wildcard is Foundayo, the FDA-approved GLP-1 pill that launched in Q2 and was not included in these results. Early prescription data showed just 3,707 scripts in the week ended April 17, below analyst expectations of around 8,000, making its ramp the key watch item for the rest of 2026 as Lilly competes head-on with Novo Nordisk's rival pill. (Invezz)
Analyst commentary suggests Mounjaro is on track to become the world's best-selling drug, further supporting Lilly's valuation prospects. (Quartz)
Eli Lilly shares are up 8% in trading on April 30, on track for their biggest single-day gain in three months, after a Q1 2026 earnings report that smashed Wall Street expectations across the board.
Revenue rose 56% year-over-year to $19.8 billion, well above the $17.62 billion consensus, while adjusted EPS came in at $8.55, crushing expectations of $6.66. The engine behind the beat was familiar: Mounjaro revenues soared 125% to $8.66 billion, beating estimates by more than $1 billion, while Zepbound generated $4.16 billion in US revenue, up 80% year-over-year. Together, GLP-1 drugs accounted for roughly two-thirds of total sales. (CNBC, Invezz)
On guidance, Lilly raised full-year 2026 revenue guidance to $82 to $85 billion, up $2 billion from prior estimates, and lifted adjusted EPS guidance to $35.50 to $37 per share. (CNBC)
The new wildcard is Foundayo, the FDA-approved GLP-1 pill that launched in Q2 and was not included in these results. Early prescription data showed just 3,707 scripts in the week ended April 17, below analyst expectations of around 8,000, making its ramp the key watch item for the rest of 2026 as Lilly competes head-on with Novo Nordisk's rival pill. (Invezz)
Analyst commentary suggests Mounjaro is on track to become the world's best-selling drug, further supporting Lilly's valuation prospects. (Quartz)